IDEXX Q4 revenue $1.09B (+14% YoY), EPS $3.08 (+18%); guides FY26 rev $4.63B-$4.72B

IDEXX LABORATORIES INC /DE

2025-FY EPS reported $13.08 revenue$4,303,702,000

Q4 revenue $1,091M (+14% as reported, +12% organic); EPS $3.08 (+18% as reported, +17% comparable).
Full year 2025 revenue $4,304M (+10%); EPS $13.08 (+23% reported, +14% comparable).
CAG Diagnostics recurring revenue grew 12% reported; record >1,900 IDEXX inVue Dx placements in Q4.
FY26 guidance: rev $4,632M-$4,720M (7.6%-9.6% reported growth); EPS $14.29-$14.80 (9%-13% growth).
Operating margin expanded 150 bps reported in Q4 to 28.9%; gross margin 60.3%, up 50 bps.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.